Last reviewed · How we verify
Oral RPV
Oral RPV (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase to prevent viral replication.
Oral RPV (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection (treatment-naive and treatment-experienced patients).
At a glance
| Generic name | Oral RPV |
|---|---|
| Also known as | Rilpivirine |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
RPV binds to the non-nucleoside binding pocket of HIV reverse transcriptase, inhibiting the enzyme's ability to convert viral RNA into DNA. This prevents integration of viral genetic material into the host cell genome and blocks HIV replication. It is used as part of combination antiretroviral therapy for HIV-1 infection.
Approved indications
- HIV-1 infection (treatment-naive and treatment-experienced patients)
Common side effects
- Rash
- Nausea
- Headache
- Diarrhea
- Elevated liver enzymes
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies (PHASE2)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (PHASE3)
- HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots
- Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) (PHASE4)
- Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs (PHASE2)
- More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral RPV CI brief — competitive landscape report
- Oral RPV updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI